The results of this study show that MBP fragments encapsulated in mannosylated liposomes effectively suppress the development of EAE in DA rats, reducing the severity of the first attack and facilitating recovery from the exacerbation stage.
Negative LGT proteome fingerprint in the serum of patients with malignant tumors could be viewed as the stationary phase, while the positive LGT proteome could be viewed as the exacerbation stage.
No individuals used inhalers or spray treatments during the acute exacerbation stage of COPD, which is well below the normal rate of inhaler use of approximately 10%, reported by Restrepo et al.[ 33].
The results show that liposome-encapsulated MBP46 62 is the most effective in reducing maximal disease score during the first attack, while MBP124 139 and MBP147 170 can completely prevent the development of the exacerbation stage.
26 Furthermore, there is the potential that early patient and physician identification of an impending exacerbation may assist in treating patients at a milder exacerbation stage who may not require hospitalization, and the associated increased expenditure relative to home-based care.
In tests of liposome-encapsulated MBP peptides on DA rats developing EAE, p1 mSUV was the most efficient in reducing general severity of EAE, mainly during the first attack, while p2 mSUV and p3 mSUV effectively prevented the development of the exacerbation stage.
Whereas early-stage effects may be due to decreased recruitment of neutrophils (Drechsler et al, 2010) or monocytes, the exacerbation at later stages may reflect effects favoring macrophage accumulation or a stimulation of T-cell-driven immune responses (Braunersreuther et al, 2007).
Baseline ex-smokers with COPD may have a more advanced disease than the COPD cases in the other smoking categories and our findings may also reflect the high risk of exacerbation at advanced stages of COPD (with the disease process causing both stress and exacerbations).
In the present multicentric retrospective study, the clinical significance of serum sIL-2R measurement in relation to laboratory and clinical measures of disease activity was evaluated in patients with IM during period of disease exacerbation and/or inactive stages of the disease and compared to controls including patients with noninflammatory elevated CK levels.
